Drugs / CAR20(NAP)-T
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06002659 | May 2024 → Dec 2027 expected | lymphoma | Uppsala University | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-10 | Elicera Therapeutics | Results Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans elicera.com ↗
At the conference, the company will present initial data from the ongoing clinical Phase I/IIa CARMA study, which show complete tumor remission in the first patient one month after treatment. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-10 | Elicera Therapeutics | Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans elicera.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR20(NAP)-T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06002659 ↗ |
| Action | Deplete | “A cancer patient's T cells can be isolated and engineered to express a chimeric antigen receptor (CAR), which re-directs the T cells to recognize and kill tumor cells...” NCT06002659 ↗ |
| Modality | Cell therapy | “Autologous CAR-T cells targeting CD20 and upon target recognition express and secrete NAP” NCT06002659 ↗ |
| Route | Intravenous | “followed by one dose of CAR20(NAP)-T cell infusion intravenously” NCT06002659 ↗ |